Buyers Place Greater Weight on Practical Experience When Choosing Advanced Therapy Advisors

Scientific expertise remains a core requirement when selecting an advisory firm, but it is no longer the only factor shaping buying decisions in the advanced therapies sector. Development teams are asking more practical questions before bringing in outside consultants. They want to understand whether an advisory firm can help guide real development decisions, not simply provide technically sound recommendations that are difficult to put into practice.

That change reflects the nature of advanced therapy development. Programs typically move through several stages, requiring close coordination between research, manufacturing and quality teams. Decisions made in one area often affect work somewhere else, which has increased the value of advice that takes the wider development process into account.

Choosing an advisory partner has become a more thorough evaluation than it once was. Technical capability still carries significant weight, but buyers also look at how consultants communicate, work with project teams and respond when development plans change. The expectation is no longer that advisors operate independently. They are increasingly expected to become part of the development effort.

Procurement talks have changed along with those expectations. Companies now take time to learn how advisory firms help during the building phases and how they share ideas with different people working on a project. Even if a suggestion is correct, in terms of it can hold things back if teams have trouble using it in their daily tasks.

The pace of advanced therapy development is changing all the time. Advanced therapy development is not always straightforward. Programs do not always go as planned. New information can come up. This can change what needs to be done. Advanced therapy development plans need to be changed as things happen. People who are buying services want to work with advisors who can keep up with therapy development. They do not want to work with advisors who only do what was originally planned for therapy development.

This flexibility can be especially valuable for smaller biotechnology companies. Lean development teams often depend on external specialists to support a wider range of activities as programs move forward. Advisors are not expected to replace internal expertise, but they can strengthen decision-making where specialized knowledge is limited.

Large pharmaceutical companies often have reasons for hiring outside advisors. Many already have research and manufacturing teams, yet they still bring in consultants to look at complicated technical issues or offer a fresh view on major development choices. In these cases, people who buy these services usually prefer advisors who can fit well into existing systems of making things more complicated.

Communication has become another point of comparison. Advanced therapy programs involve people with different technical backgrounds and responsibilities. Advisory firms are increasingly expected to explain recommendations in a way that supports productive discussions across project teams instead of limiting conversations to highly specialized technical language.

Longer working relationships are also becoming more common. Rather than hiring consultants for a single assignment, some organizations keep the same advisory firm involved across several stages of development. That continuity helps preserve context, reduces repeated handovers and allows earlier recommendations to remain relevant as the program progresses.

For buyers, the choice is becoming more about how knowledge turns into real help. Scientific facts are still important. They are just one part of the check. Companies are looking at whether a consulting group can help teams make choices all along the way. In situations, the quality of the connection is not about how many technical reports are made but about whether the advice keeps the project going the right way.